Bitcoin sets a new all-time high above $6,000 >>> READ MORE

3 Pharmaceutical Stocks to Sell Now

WCRX, SGNT, PTX slump in weekly rankings


The ratings of three Pharmaceutical stocks are down this week, according to the Portfolio Grader database. Each of these rates a “D” (“sell”) or “F” overall (“strong sell”).

This week, Warner Chilcott (NASDAQ:WCRX) falls to a D (“sell”), worse than last week’s grade of C (“hold”). Warner Chilcott engages in the development, manufacture, and promotion of branded pharmaceutical products focusing on the women’s healthcare, gastroenterology, dermatology, and urology markets in North America and western Europe. The stock price has fallen 13% over the past month, worse than the 3.2% decrease the Nasdaq has seen over the same period of time. To get an in-depth look at WCRX, get Portfolio Grader’s complete analysis of WCRX stock.

Sagent Pharmaceuticals (NASDAQ:SGNT) earns a F (“strong sell”) this week, moving down from last week’s grade of D (“sell”). Sagent Holding Co is an injectable pharmaceutical company that develops and sources products which they sell primarily in the United States. The stock gets F’s in Earnings Revisions and Equity. Wall Street appears to agree with the stock downgrade, with share prices dropping 7.7% over the past month. For more information, get Portfolio Grader’s complete analysis of SGNT stock.

The rating of Pernix Therapeutics Holdings (AMEX:PTX) declines this week from a C to a D. Pernix Therapeutics Holdings acquires, develops, and markets medications for the pediatric market. The stock gets F’s in Earnings Momentum and Earnings Revisions. The stock’s trailing PE Ratio is 32.80. To get an in-depth look at PTX, get Portfolio Grader’s complete analysis of PTX stock.

Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.

Article printed from InvestorPlace Media,

©2017 InvestorPlace Media, LLC